TUBERCULOSIS
Conditions
Brief summary
proportion of participants with one or more SAE (i.e. grade 3 or 4 AE) at 8 weeks of treatment
Detailed description
Eficaccy: The proportion of participants with a favorable outcome at 8 weeks of treatment, Tolerability: proportion of participants having one or more AE in the prospective cohort., efficacy: time to sputum culture conversion from positive to negative, Correlation of the AUC/MIC values with time to sputum culture conversion adjusted with other explanatory covariates, changes in quality of life questionnaires and in TB associated costs from all sites will be depicted
Interventions
DRUGRifampicin 150 mg Capsules
DRUGRIMSTAR®
Sponsors
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proportion of participants with one or more SAE (i.e. grade 3 or 4 AE) at 8 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Eficaccy: The proportion of participants with a favorable outcome at 8 weeks of treatment, Tolerability: proportion of participants having one or more AE in the prospective cohort., efficacy: time to sputum culture conversion from positive to negative, Correlation of the AUC/MIC values with time to sputum culture conversion adjusted with other explanatory covariates, changes in quality of life questionnaires and in TB associated costs from all sites will be depicted | — |
Countries
Netherlands, Spain
Outcome results
None listed